Welcome to our dedicated page for Creative Medical Technology Holdings news (Ticker: CELZ), a resource for investors and traders seeking the latest updates and insights on Creative Medical Technology Holdings stock.
Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) is a pioneering biotechnology holding company dedicated to advancing regenerative medicine. Headquartered in Phoenix, Arizona, the company was incorporated in 1998 and operates as a subsidiary of Creative Medical Health, Inc. It leverages innovative stem cell research to develop therapeutic applications aimed at treating male and female sexual dysfunction, infertility, miscarriages, and related health issues.
The company's flagship product, marketed under the brand name CaverStem, specifically addresses erectile dysfunction (ED). CaverStem is offered to physicians to help patients suffering from ED through stem cell-based therapies.
In recent developments, Creative Medical Technology Holdings has seen notable success in the allogeneic cell therapy market. In Q4 2022, the company unveiled the development of AlloStem™, a cell line derived from human perinatal tissue, which incorporates a Master Cell Bank and a Drug Master File. The FDA has granted approval for the CELZ-201 program, allowing it to be used in early clinical trials for type 1 diabetes. The AlloStem™ line is also being employed in the company's StemSpine® procedure to treat chronic back pain, demonstrating significant reductions in narcotic usage and pain scores among treated patients.
Allogeneic cell therapy, a cornerstone of the company's research, involves using donated cells from a healthy individual to treat patients with otherwise intractable diseases. These therapies have shown great potential in providing curative options where traditional treatments have failed.
Creative Medical Technology is heavily involved in multiple clinical trials and continues to secure necessary regulatory approvals. The company’s financial health remains robust, with significant cash reserves and no long-term debt. Furthermore, Creative Medical Technology has built a strong intellectual property portfolio with over 68 patents and pending applications.
As of the latest updates, the FDA has cleared the company to proceed with a Phase 1/2 clinical trial of StemSpine® using AlloStem™ (CELZ-201-DDT) for chronic lower back pain. The IRB approval has been received, paving the way for a placebo-controlled study that will assess the safety, efficacy, and tolerability of the treatment.
Overall, Creative Medical Technology Holdings is poised at the forefront of regenerative medicine, leveraging cutting-edge stem cell technologies to develop transformative therapies for chronic and debilitating conditions. The company’s ongoing clinical trials and strategic partnerships underline its commitment to medical innovation and improving patient outcomes globally.
Creative Medical Technology Holdings, Inc. (OTC-CELZ) announced a 1-for-500 reverse stock split, effective November 10, 2021, to facilitate its planned listing on The Nasdaq Capital Market. The reverse split will reduce outstanding shares from 1,226,141,742 to 2,452,348 without altering stockholder equity percentages. The temporary ticker symbol during this process will be CELZD, reverting to CELZ upon Nasdaq listing. The company aims to enhance its visibility and shareholder value through this strategic move.
Creative Medical Technology Holdings Inc. (OTC-CELZ) announced promising proof of concept data for its ImmCelz™ immunotherapy. This innovative product, utilizing a patent-pending 'ex vivo cell-free' reprogramming protocol, shows potential to reprogram patient immune cells effectively. The study, conducted at the University of Miami, indicates ImmCelz™ may enable rapid clinical translation, aiming to suppress harmful immune responses associated with autoimmune diseases. The company has filed an IND with the FDA related to stroke treatment. The autoimmunity market is valued in the billions, highlighting significant growth potential.
Creative Medical Technology Holdings (OTC – CELZ) announced the filing of a new patent for nanoparticles known as 'exosomes' derived from its MyeloCelz™ platform, aimed at treating type 1 diabetes. The patent includes the use of these exosomes in combination with other agents promoting immunological tolerance.
Notable experts, including Dr. Camillo Ricordi, praised the innovation, highlighting the potential to specifically target harmful T cells without affecting the body's defenses. This advancement could revolutionize treatment for type 1 diabetes and related autoimmune diseases.
Creative Medical Technology Holdings (OTC: CELZ), a biotechnology company, announced its partnership with Elite Med Listings Inc. on Sept. 16, 2021. This engagement aims to accelerate the adoption of their CaverStem® treatment, which focuses on regenerative medicine. Angela Chatterfield, CEO of Elite Med Listings, expressed confidence in the treatment's efficacy and safety after conducting thorough research. Timothy Warbington, CEO of Creative Medical Technology, looks forward to the collaboration, anticipating a significant business impact.
Creative Medical Technology Holdings, Inc. (CELZ) announced a definitive agreement for a private placement, raising approximately $3,788,000 from accredited institutional investors. The offering includes 15% Original Issue Discount Senior Notes totaling around $4,456,000, maturing on February 11, 2022. Additionally, the company will issue warrants for 157,184,354 shares of common stock, with an initial exercise price of $0.02835 for a five-year period. Roth Capital Partners is the sole placement agent, with the closing expected on August 11, 2021.
Creative Medical Technology Holdings (OTC – CELZ) has announced the launch of its second Regenerative Immunology product, MyeloCelz™, which focuses on utilizing the innate immune system to promote healing. This innovative approach complements the existing ImmCelz™ product, which activates the body’s stem cells primarily through T and B cells. With a focus on personalized therapy, MyeloCelz™ aims to enhance safety and efficacy. The company’s products are backed by comprehensive patent applications, highlighting its commitment to advancing immunotherapy for degenerative conditions.
Creative Medical Technology Holdings (CELZ) has appointed Dr. Courtney Bartlett to lead clinical development for its therapeutic products. Dr. Bartlett brings a decade of experience in cell and gene therapy, having contributed to high-profile stem cell trials. She will prioritize collaborating with the FDA to secure Investigational New Drug application clearance for upcoming stroke treatment trials. The company's existing products, including Caverstem® and StemSpine®, show clinical promise as it aims to expand its pipeline in regenerative medicine.
Creative Medical Technology Holdings (OTC - CELZ) announced its virtual presentation at the World Stem Cell Summit on June 17, 2021, at 12:00pm EST. The session will include a 20-minute presentation followed by a Q&A session moderated by a representative from Noble Capital Markets. Interested participants can register for free at channelchek.com. The presentation will highlight the company's ImmCelz® subsidiary and is part of a broader initiative to foster biomedical research and investment in regenerative medicine.
Creative Medical Technology Holdings (CELZ) has filed a provisional patent application for its ImmCelz® personalized cell therapy product, demonstrating its potential to suppress autoimmune diabetes. Recent experiments revealed that ImmCelz® enhances the effects of BCG and GM-CSF in preventing diabetes by increasing myeloid suppressor cell activity. The company's focus on innovative immunological pathways is expected to strengthen its intellectual property during the FDA approval process. ImmCelz® has also shown promising results in preclinical models related to various medical conditions.
Creative Medical Technology Holdings (CELZ) announced promising preclinical data suggesting ImmCelz® could treat Parkinson's Disease. Using the MPTP mouse model, ImmCelz® inhibited Parkinsonism-like behavior and protected dopamine cells, enhancing interleukin-10 levels. With over 1 million Parkinson's patients in the USA, this innovation represents a significant market opportunity. The company aims to advance its lead indication, stroke, and address FDA comments before initiating human trials. Overall, this expansion could bolster CELZ's product pipeline in regenerative immunotherapy.
FAQ
What is the current stock price of Creative Medical Technology Holdings (CELZ)?
What is the market cap of Creative Medical Technology Holdings (CELZ)?
What does Creative Medical Technology Holdings, Inc. specialize in?
What is CaverStem?
What is AlloStem™?
What are the latest developments in Creative Medical Technology's clinical trials?
How does allogeneic cell therapy work?
What is the company's financial condition?
How is the company contributing to pain management?
What are some of the company's key partnerships?
Where is Creative Medical Technology Holdings located?
What is the ticker symbol for Creative Medical Technology Holdings, Inc.?
